Rani announces oral delivery of monoclonal antibody via high-capacity pill

Rani Therapeutics Holdings announced the successful oral delivery of a monoclonal antibody, Humira adalimumab via its high-capacity capsule, the RaniPill HC, in a preclinical study. “The preclinical results we are sharing today show the potential of the RaniPill platform to orally deliver large molecules, such as antibodies, at high volume, which could enable the replacement of many injectable drugs with an oral pill,” said Mir Hashim, PhD, Chief Scientific Officer for Rani Therapeutics. “The high-capacity version, the RaniPill HC, is capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule and has achieved a cumulative greater than90% success rate for delivery across multiple preclinical studies. The data generated to date with the RaniPill HC give us confidence as we progress the high-capacity device towards clinical readiness.”